ClinicalTrials.gg

Program

remdesivir

Also written as “Remdesivir”, “Remdesivir (RDV)” and “RDV”.

Its studies are mostly in COVID-19, led by 4 companies.

Furthest: phase 3, since Feb 28, 20209 company-led studies, 1 open or runningNext primary completion: Sep 28, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences60 open or runningphase 3since Feb 28, 2020Feb 28, 2020none ahead
Biomed Industries10 open or runningphase 1since Jul 13, 2020Jul 13, 2020none ahead
Dr. Md. Alimur Reza10 open or runningphase 2since Oct 20, 2020Oct 20, 2020none ahead
Pfizer11 open or runningphase 3since May 5, 2025May 5, 2025Sep 28, 2027phase 3 · NCT07013474

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 28, 2020First studies: 2 phase 3 studies in COVID-19New to Gilead SciencesGilead Sciences · NCT04292899, NCT04292730
  2. Jun 8, 2020Phase 3 study in COVID-19Gilead Sciences · NCT04431453 · 59 enrolled · United States, Italy, Spain and more
  3. Jul 13, 2020Biomed Industries's first study: phase 1 study in COVID-19New to Biomed IndustriesBiomed Industries · NCT04480333 · 45 enrolled · United States
  4. Aug 5, 2020Phase 3 study in COVID-19Gilead Sciences · NCT04501952 · 584 enrolled · United States, Denmark, Spain and more
  5. Aug 26, 2020Phase 2 study in COVID-19Gilead Sciences · NCT04539262 · 156 enrolled · United States
  6. Oct 20, 2020Dr. Md. Alimur Reza's first study: phase 2 study in COVID-19New to Dr. Md. Alimur RezaDr. Md. Alimur Reza · NCT04596839 · 60 enrolled · Bangladesh
  7. Feb 8, 2021Phase 3 study in COVID-19Gilead Sciences · NCT04745351 · 249 enrolled · United States, Brazil, Portugal and more
  8. May 5, 2025Pfizer's first study: phase 3 study in COVID-19New to PfizerPfizer · NCT07013474 · 300 planned · United States, Argentina, Belgium and more

Ahead

  1. Sep 28, 2027Primary completion: phase 3 study in COVID-19Pfizer · NCT07013474

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“RNA-directed RNA polymerase L inhibitor; Replicase polyprotein 1ab inhibitor”ChEMBL 37, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07013474COVID-19 · United States, Argentina, Belgium and more3RecruitingPfizerSep 28, 2027300
NCT04745351COVID-19 · United States, Brazil, Portugal and more3TerminatedGilead SciencesApr 20, 2022249
NCT04596839COVID-19 · Bangladesh2CompletedDr. Md. Alimur RezaApr 30, 202160
NCT04539262COVID-19 · United States2CompletedGilead SciencesFeb 26, 2021156
NCT04501952COVID-19 · United States, Denmark, Spain and more3TerminatedGilead SciencesMay 6, 2021584
NCT04480333COVID-19 · United States1UNKNOWNBiomed IndustriesDec 31, 202045
NCT04431453COVID-19 · United States, Italy, Spain and more3CompletedGilead SciencesFeb 10, 202359
NCT04292899COVID-19 · United States, China, France and more3CompletedGilead SciencesApr 9, 20204,891
NCT04292730COVID-19 · United States, China, France and more3CompletedGilead SciencesApr 29, 20201,113

How it is read

Names in the registry

  • “Remdesivir”, 5 entries
  • “remdesivir”, 1 entry
  • “Remdesivir (RDV)”, 1 entry
  • “RDV”, 1 entry
  • “Drug: GS-5734 - 1.00 mg/kg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.